Polyrizon launches preclinical studies for intranasal naloxone to combat opioid overdose using cutting-edge platform

Raanana, israel, march 13, 2025 (globe newswire) -- polyrizon ltd. (nasdaq: plrz) (the "company" or "polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, previously announced the initiation of preclinical studies for intranasal naloxone, a life-saving opioid overdose treatment.
PLRZ Ratings Summary
PLRZ Quant Ranking